CE / CME
In this on-demand webcast, an expert reviews the pathophysiology, risk assessment, prevention, and management of tumor lysis syndrome (TLS), a potentially life-threatening oncologic emergency associated with hematologic malignancies and certain anticancer therapies. The faculty examines disease-, patient-, and treatment-related risk factors for TLS, including tumor burden, renal function, and the use of novel agents such as venetoclax, bispecific antibodies, and CAR T-cell therapies. Clinical evidence and practical considerations for TLS prevention and management are highlighted, including risk stratification, laboratory monitoring, hydration, correction of electrolyte abnormalities, and uric acid–lowering therapies such as allopurinol, febuxostat, and rasburicase. Particular attention is given to TLS risk mitigation during venetoclax initiation in CLL and AML, including dose ramp-up strategies, laboratory monitoring schedules, and criteria for inpatient versus outpatient treatment. Case-based discussions and institutional protocol considerations emphasize individualized prophylaxis, early recognition of metabolic disturbances, multidisciplinary coordination, and standardized approaches to TLS management to reduce complications and support the safe administration of anticancer therapies.
Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit
Pharmacists: 1.00 contact hour (0.1 CEUs)
ABIM MOC: maximum of 1.00 Medical Knowledge MOC point
Physicians: maximum of 1.00 AMA PRA Category 1 Credit™
Nurse Practitioners/Nurses: 1.00 Nursing contact hour
Released: October 28, 2026
Expiration: April 27, 2027
Share
Provided by Clinical Care Options, LLC dba Decera Clinical Education.
This activity is supported by an educational grant from Sanofi Genzyme.
Sanofi Genzyme
This activity is intended for hematologists, oncologists, emergency room specialists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients at risk of developing tumor lysis syndrome.
This activity aims to improve learners’ knowledge, confidence, and competence at preventing, identifying, and managing tumor lysis syndrome in patients with hematologic malignancies.
Upon completion of this activity, participants should be able to:
Identify patients with hematologic malignancies at risk for developing TLS
Apply best practices for TLS prevention and management through evidence-based use of uric acid–lowering agents and supportive care
Optimize institutional protocols to standardize risk stratification, prophylaxis, treatment initiation, and shared decision-making in patients with hematologic malignancies at risk of TLS
Evaluate the potential clinical implications of the evolving evidence on TLS related to venetoclax, bispecific antibodies, CAR T-cells, and other emerging therapies
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary AuthorDonald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP: consultant/advisor/speaker: Genentech, Genmab, GSK, Incyte, Johnson & Johnson, Lilly, Sanofi.
The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below:
Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Stemline.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2026, through April 27, 2027:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Generative artificial intelligence (AI) tools were used for drafting educational content, revising or refining educational content, generating clinical case(s) or scenario(s), and drafting assessment question(s) and/or rationale(s). All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.
Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.
Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-614-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until April 27, 2027. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.
CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported credit. Visit CME cmepassport.org to create your account.